These stocks are bargains.
News & Analysis: Illumina
They're leaders in their markets. And those markets should grow tremendously.
These companies focused on genetics, glamor, and gaming are worth considering for the long haul.
The gene sequencing pioneer could face several scenarios in the future -- from very good to very bad.
Find out why this team of Motley Fool contributors believe these businesses are strong buys right now.
ILMN earnings call for the period ending March 31, 2019.
The gene-sequencing leader's revenue and earnings growth rates slowed down in the first quarter, but stronger growth is likely on the way.
The gene-sequencing pioneer isn't likely to hit a home run in Q1. But Illumina should run up the score later in 2019.
The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.